169 related articles for article (PubMed ID: 26450638)
41. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
42. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
43. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
44. Pseudo-hypopyon as the presenting feature in B-cell and T-cell intraocular lymphoma.
Lobo A; Larkin G; Clark BJ; Towler HM; Lightman S
Clin Exp Ophthalmol; 2003 Apr; 31(2):155-8. PubMed ID: 12648051
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
46. Complete Endoscopic and Histopathological Remission of Mantle Cell Lymphoma of the Gastrointestinal Tract.
Mohy-Ud-Din N; Guha A; Mitre M
Cureus; 2019 Mar; 11(3):e4350. PubMed ID: 31187015
[TBL] [Abstract][Full Text] [Related]
47. Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma.
Rašić DM; Knežević M; Terzić T; Vlajković G
Surv Ophthalmol; 2017; 62(1):83-88. PubMed ID: 27256688
[TBL] [Abstract][Full Text] [Related]
48. Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease.
Raderer M; Püspök A; Birkner T; Streubel B; Chott A
Leuk Lymphoma; 2004 Jul; 45(7):1459-62. PubMed ID: 15359648
[TBL] [Abstract][Full Text] [Related]
49. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
51. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
52. Blastoid Variant of Mantle Cell Lymphoma with Leukemic Presentation - A Rare Case Report.
Khanna R; Belurkar S; Lavanya P; Manohar C; Valiathan M
J Clin Diagn Res; 2017 Apr; 11(4):ED16-ED18. PubMed ID: 28571156
[TBL] [Abstract][Full Text] [Related]
53. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
54. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
55. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
[TBL] [Abstract][Full Text] [Related]
56. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.
Sohn SK; Baek JH; Kim DH; Jung JT; Kwak DS; Park SH; Suh JS; Lee KB
Am J Hematol; 2000 Sep; 65(1):75-80. PubMed ID: 10936869
[TBL] [Abstract][Full Text] [Related]
57. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases.
Yatabe Y; Suzuki R; Matsuno Y; Tobinai K; Ichinohazama R; Tamaru J; Mizoguchi Y; Hashimoto Y; Yamaguchi M; Kojima M; Uike N; Okamoto M; Isoda K; Ichimura K; Morishima Y; Seto M; Suchi T; Nakamura S
Pathol Int; 2001 Oct; 51(10):747-61. PubMed ID: 11881727
[TBL] [Abstract][Full Text] [Related]
58. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
59. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.
Weisenburger DD; Vose JM; Greiner TC; Lynch JC; Chan WC; Bierman PJ; Dave BJ; Sanger WG; Armitage JO
Am J Hematol; 2000 Jul; 64(3):190-6. PubMed ID: 10861815
[TBL] [Abstract][Full Text] [Related]
60. Current treatment approaches for mantle-cell lymphoma.
Witzig TE
J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
